HeartBeam director granted options for 51,724 shares

HeartBeam, Inc. director George de Urioste received a grant of options to acquire 51,724 shares of common stock at an exercise price of $1.43 per share.

Rhea-AI Filing Summary

HeartBeam, Inc. director George de Urioste received a grant of options to acquire 51,724 shares of common stock at an exercise price of $1.43 per share. Following this award, he holds options covering 51,724 shares.

According to the grant terms, one half of the shares subject to this "Special Option" vest on March 31, 2026, with the remaining half vesting on June 30, 2026, based on a vesting commencement date of January 1, 2026. The options expire on January 1, 2036 and were issued under HeartBeam’s 2022 Equity Incentive Plan.

Insider Trade Summary

Grant/Award: 51,724 shares

Grant/Award 1 txn

Insider de Urioste George

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock (right to buy)	51,724	$0.00	$0.00

Holdings After Transaction: Common Stock (right to buy) — 51,724 contracts (Direct)

Footnotes (1)

1. F1. Granted options on February 9, 2026 (the "Special Option"), one half of the total number of shares of common stock (the "Shares") subject to the Special Option shall vest on March 31, 2026, the three-month anniversary of the vesting commencement date beginning January 1, 2026, and the remaining Shares of common stock shall vest on June 30, 2026, the six-month anniversary of the vesting commencement date. These options have been issued from the Company's 2022 Equity Incentive Plan.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did HeartBeam (BEAT) report for George de Urioste?

HeartBeam reported an option grant to director George de Urioste. He received options to acquire 51,724 shares of common stock at an exercise price of $1.43 per share, representing a compensation-related award rather than an open-market stock purchase or sale.

How many HeartBeam (BEAT) shares are covered by the new option grant?

The new option grant covers 51,724 HeartBeam common shares. All 51,724 shares are underlying a single "Special Option" award, and this figure also represents de Urioste’s total option holdings following the reported transaction.

What is the exercise price of George de Urioste’s HeartBeam (BEAT) options?

The options have an exercise price of $1.43 per share. This means de Urioste can buy HeartBeam common stock at $1.43 for each of the 51,724 optioned shares, subject to vesting and before the stated expiration date.

When do George de Urioste’s HeartBeam (BEAT) options vest?

The options vest in two tranches during 2026. Half of the 51,724 shares vest on March 31, 2026, and the remaining half vest on June 30, 2026, based on a January 1, 2026 vesting commencement date.

When do the newly granted HeartBeam (BEAT) options expire?

The granted options expire on January 1, 2036. De Urioste may exercise vested portions of the 51,724-share option at $1.43 per share any time before this expiration date, consistent with the terms of HeartBeam’s 2022 Equity Incentive Plan.

Are George de Urioste’s HeartBeam (BEAT) options part of a company equity plan?

Yes, the options were issued under HeartBeam’s 2022 Equity Incentive Plan. The footnote specifies that this Special Option grant comes from the company’s established equity incentive program, reflecting standard director compensation practices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/23/2026 - 05:31 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

de Urioste George

(Last) (First) (Middle)

2118 WALSH AVE, SUITE 210

(Street)

SANTA CLARA CALIFORNIA 95050

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HeartBeam, Inc. [ BEAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock (right to buy)	$1.43	02/09/2026		A		51,724		(1)	01/01/2036	Common Stock	51,724	$0	51,724	D

Explanation of Responses:

1. Granted options on February 9, 2026 (the "Special Option"), one half of the total number of shares of common stock (the "Shares") subject to the Special Option shall vest on March 31, 2026, the three-month anniversary of the vesting commencement date beginning January 1, 2026, and the remaining Shares of common stock shall vest on June 30, 2026, the six-month anniversary of the vesting commencement date. These options have been issued from the Company's 2022 Equity Incentive Plan.

	/s/ George de Urioste	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)